Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

3.870 -0.170 (-4.21%)
Delayed Quote Updated: 3:36 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Outlook For Aquestive Therapeutics ↗
 
Via Benzinga
News headline image
Aquestive Inks Supply Pact For Its Seizure Treatment Covering European, Middle East Countries ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive's AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray 
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Looking Into Aquestive Therapeutics's Return On Capital Employed ↗
According to data from Benzinga Pro, during Q3, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $11.46 million. Despite a 23.1% increase in earnings, the company posted a loss of $12.54... 
Via Benzinga
News headline image
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Earnings Preview ↗
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
NASDAQ:AQST Investor Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 09/29/2022 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation on over potential breaches of fiduciary duties. 
Via SBWire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million. 
Via Benzinga
News headline image
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket ↗
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million. 
Via Benzinga
News headline image
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival ↗
Aquestive Therapeutics (AQST) stock is taking off Tuesday as investors react to positive clinical trial data from the pharmaceutical company. 
Via InvestorPlace
News headline image
Why Is Aquestive Therapeutics Stock Up Today? ↗
Aquestive Therapeutics Inc (NASDAQ: AQST) shares are trading higher Tuesday after the company announced results from the EPIPHAST II trial for its AQST-109 epinephrine sublingual film. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.